Drug Profile
Cytomegalovirus vaccine (Triplex) - Helocyte
Alternative Names: CMV-MVA triplex vaccine; Cytomegalovirus modified vaccinia Ankara triplex vaccine; Cytomegalovirus specific T-cells Triplex; Multi-CMV epitope modified vaccinia Ankara vaccine - Helocyte; MVA multi CMV epitopes; MVA-CMV-Triplex; TriplexLatest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator City of Hope National Medical Center
- Developer City of Hope National Medical Center; Helocyte
- Class Cytomegalovirus vaccines; Gene therapies; Immunotherapies; Peptide vaccines; T lymphocyte cell therapies; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Cytomegalovirus infections
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 11 Apr 2024 National Institute of Allergy and Infectious Diseases plans a phase II COLT trial in Cytomegalovirus infections (Prevention) in USA (IM) in December 2023 (NCT06075745)
- 16 Oct 2023 Helocyte announces option agreement with City of Hope for exclusive worldwide rights to use Triplex
- 16 Oct 2023 US FDA accepts IND for Triplex for cytomegalovirus